Spectral AI, Inc. (MDAI) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Spectral AI, Inc. is an artificial intelligence company focused on predictive medical diagnostics, specifically its DeepView System for burn wounds and diabetic foot ulcers. The company is currently in a pre-commercialization stage, generating revenue primarily through government research and development contracts, notably with the Biomedical Advanced Research and Development Authority (BARDA) and the Medical Technology Enterprise Consortium (MTEC). The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $8.17 million | $3.44 million | $21.98 million | $12.77 million |
| Gross Profit | $3.67 million | $1.47 million | $9.93 million | $5.44 million |
| Gross Margin | 44.9% | 42.8% | 45.2% | 42.6% |
| Operating Loss | $(0.89) million | $(4.17) million | $(5.47) million | $(10.06) million |
| Net Loss | $(1.50) million | $(10.63) million | $(7.57) million | $(17.31) million |
| Cash and Equivalents | $3.70 million (as of Sept 30, 2024) | |||
| Total Debt (Notes Payable) | ~$5.97 million (Short-term: $5.0M; Long-term: $1.0M) | |||
| Accumulated Deficit | $(40.36) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 137.6% quarter-over-quarter and 72.1% year-to-date, driven by increased activity under the $150 million Project BioShield (PBS) contract with BARDA and other government awards.
- Improved Operating Performance: Operating loss narrowed significantly to $0.89 million in Q3 2024 from $4.17 million in Q3 2023. This improvement is attributed to higher revenue and a reduction in non-revenue generating R&D expenses.
- Debt Structure: The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville in March 2024, receiving $12.5 million in convertible notes (Pre-Paid Advances). As of September 30, 2024, the outstanding principal balance on these notes was approximately $4.4 million.
- Stock Issuances: The company issued shares under the B. Riley ELOC and the Yorkville SEPA to raise capital and repay debt obligations.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management believes current cash, government contracts (BARDA, MTEC), and equity facilities (B. Riley ELOC, Yorkville SEPA) are sufficient to fund operations for at least one year. The company may implement cost-saving measures to focus on the burn indication if capital becomes constrained.
- Nasdaq Compliance Risk: The company received notice from Nasdaq on June 3, 2024, regarding non-compliance with the minimum market value of listed securities requirement ($35.0 million). The company has until December 2, 2024, to regain compliance or risk delisting.
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting, specifically regarding communication of complex arrangements, recording of operating expenses/accruals, and the financial statement close process. Remediation efforts are underway.
- Legal Proceedings: The company received a draft complaint from Stifel alleging a debt of approximately $2.55 million related to a previous engagement letter. The company intends to vigorously contest the claim.
- Subsequent Events: On November 6, 2024, the company announced an intent to spin off its Spectral IP subsidiary into an independent publicly-traded company.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify if the company has met the $35 million market capitalization requirement by the December 2, 2024 deadline to avoid delisting.
- Debt Repayment Schedule: Confirm the ability to meet the Yorkville convertible note installment payments, which are due through February 2025.
- Government Contract Continuity: Monitor the status of the BARDA PBS contract and MTEC grants, which represent the vast majority of revenue (approx. 90%+).
- Internal Control Remediation: Review future filings for updates on the remediation of material weaknesses in financial reporting controls.
- Stifel Litigation: Track the resolution of the $2.55 million claim from Stifel and any potential impact on cash flow.